Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$22.60
-1.1%
$24.66
$22.43
$53.96
$1.08B0.72497,473 shs657,360 shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$31.57
+2.2%
$29.38
$23.23
$42.29
$992.87M0.64399,320 shs302,788 shs
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
$1.27
$0.85
$7.10
N/AN/AN/A87,682 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-1.14%-3.17%-13.04%-10.42%-39.52%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+2.17%+4.19%+4.54%+19.72%-1.03%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00%0.00%0.00%0.00%0.00%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.4152 of 5 stars
3.12.00.03.72.44.21.3
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.3568 of 5 stars
3.41.00.03.03.80.82.5
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.25
Hold$32.3343.07% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7538.58% Upside
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VBIV, COLL, ODT, CXRXF, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/8/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.00
4/10/2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$731.97M1.46$4.95 per share4.57$15.23 per share1.48
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.61$12.63 per share2.50$7.10 per share4.45
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$159.52M$2.768.196.875.9519.38%22.20%10.40%8/6/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2225.885.24N/A6.61%99.08%15.14%8/6/2025 (Estimated)
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
-$126.35MN/A0.00N/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A

Latest VBIV, COLL, ODT, CXRXF, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.71N/AN/AN/A$173.42 millionN/A
8/6/2025Q2 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.88N/AN/AN/A$182.26 millionN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.80
2.95
2.02
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2,02847.14 million34.36 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
14528.53 million14.58 millionNot Optionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable

Recent News About These Companies

VBI recalls PreHevbrio and winds down operations
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI craters as investors react to Hep B vaccine data
VBI Vaccines Reports Full Year 2023 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$22.60 -0.26 (-1.14%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$22.94 +0.34 (+1.50%)
As of 07/8/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$31.57 +0.67 (+2.17%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$31.58 +0.00 (+0.02%)
As of 07/8/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Odonate Therapeutics stock logo

Odonate Therapeutics NASDAQ:ODT

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.